ArticleAnnals of translational medicine2021

Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy.

Yixing Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.